Printer Friendly

ADVANCED TISSUE SCIENCES NAMES FORMER FLUOR CORP. CHAIRMAN NEW BOARD MEMBER

 ADVANCED TISSUE SCIENCES NAMES
 FORMER FLUOR CORP. CHAIRMAN NEW BOARD MEMBER
 LA JOLLA, Calif., Oct. 5 /PRNewswire/ -- Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATIS) today announced the appointment of David S. Tappan Jr. to the board of directors of the company, according to Arthur J. Benvenuto, chairman, president and chief executive officer of Advanced Tissue Sciences. Tappan is former chairman and chief executive officer of Fluor Corp., an international engineering, construction and technical services company. He is currently serving as a director for Fluor Corp. and is also a director of Genentech Inc.; Allianz Insurance Co.; Beckman Instruments Inc.; the University of Southern California Board of Trustees and The Scripps Research Institute.
 "David Tappan's experience brings a unique blend of talents to our board," said Benvenuto. "He is well respected for his strong strategic leadership and his understanding of our global economy. Mr. Tappan's experience in facilities planning will also be of great value as we scale-up and commercialize additional products."
 Tappan's addition to the board brings the total number of directors to six. He joins a board composed of the following members. Benvenuto, chairman of the board of directors, president and chief executive officer; Gail K. Naughton, Ph.D., executive vice president and chief operating officer; Jack L. Heckel, president and chief operating officer of GenCorp. Inc., a technology-based company with strong positions in aerospace, automotive and related polymer products; John Pappajohn, president and principal stockholder of Equity Dynamics Inc., a financial consulting firm, and the sole owner of Pappajohn Capital Resources, a venture capital firm; and William B. Walsh, M.D., founder of The People-to-People Health Foundation, parent organization for Project HOPE, and vice chairman of Project HOPE.
 Advanced Tissue Sciences is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow and liver.
 -0- 10/5/92
 /CONTACT: James P. Linton, Ph.D., manager of investor relations of Advanced Tissue Sciences, 619-450-5707/
 (ATIS) CO: Advanced Tissue Sciences Inc. ST: California IN: MTC SU: PER


JL-EH -- SD002 -- 6648 10/05/92 13:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 5, 1992
Words:367
Previous Article:CNG $150 MILLION DEBENTURES RATED 'AA' BY FITCH, OUTSTANDING DEBT AFFIRMED -- FITCH FINANCIAL WIRE --
Next Article:HENKEL CORPORATION COMMISSIONS FATTY ALCOHOL PLANT
Topics:


Related Articles
Spotlight on environmentalists.
PUCKETT RETIRES FROM FLUOR BOARD
FORMER FLUOR CORP. DIRECTOR DIES
ADVANCED TISSUE SCIENCES APPOINTS VICE PRESIDENT, PROCESS DEVELOPMENT
ADVANCED TISSUE SCIENCES NAMES GAIL R. WILENSKY, PH.D., TO BOARD OF DIRECTORS
VILMA S. MARTINEZ ELECTED TO FLUOR BOARD OF DIRECTORS
FLUOR DANIEL AWARDED CONTRACT BY ADVANCED TISSUES SCIENCES
Advanced Tissue Sciences Appoints Ronald L. Nelson to the Board of Directors
eps corp Adds Former Fluor President Charles Oliver to Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters